Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was upgraded by equities researchers at B. Riley to a "strong-buy" rating in a report issued on Thursday,Zacks.com reports.
A number of other research analysts also recently issued reports on the company. BTIG Research raised their price target on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Zacks Research upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research note on Tuesday, June 17th. Finally, Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Three investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat.com, Theravance Biopharma currently has an average rating of "Strong Buy" and an average target price of $23.00.
Get Our Latest Research Report on TBPH
Theravance Biopharma Stock Up 4.4%
NASDAQ:TBPH opened at $14.30 on Thursday. The stock's 50 day moving average price is $12.39 and its 200 day moving average price is $10.59. The company has a market capitalization of $720.15 million, a PE ratio of 59.58 and a beta of 0.05. Theravance Biopharma has a 52-week low of $7.88 and a 52-week high of $14.55.
Insider Buying and Selling at Theravance Biopharma
In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares in the company, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP grew its stake in shares of Theravance Biopharma by 11.9% in the 1st quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company's stock valued at $1,628,000 after purchasing an additional 19,363 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Theravance Biopharma by 3.8% in the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after buying an additional 2,293 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Theravance Biopharma by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock valued at $1,049,000 after buying an additional 1,720 shares during the period. ProShare Advisors LLC acquired a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $119,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Theravance Biopharma by 27.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company's stock valued at $1,412,000 after buying an additional 32,534 shares during the period. 99.10% of the stock is currently owned by hedge funds and other institutional investors.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
